Codiak BioSciences Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of Well-Validated Cancer Immunotherapy Pathways

On April 10, 2021, Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today reported new preclinical evidence from Codiak’s exoASO-STAT6 program and clinical results from the healthy volunteer portion of the ongoing Phase 1 trial of Codiak’s exoIL-12 program at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 (Week 1: April 9-14; Week 2: May 17-21) ( These data illustrate the potential of engineered exosomes to target previously undruggable, but well-validated, pathways in cancer immunotherapy and generate potent single-agent activity. “We now have a growing body of preclinical and clinical evidence across our pipeline programs demonstrating that engineering exosomes to deliver potent drug molecules enhances the therapeutic index of pathways known to drive the immune response to fighting tumors,” said Douglas E. Williams, PhD, President and Chief Executive Officer of Codiak. “In particular, data from multiple in vitro and in vivo studies of engineered exosomes incorporating an antisense oligonucleotide demonstrate potent single-agent and highly selective genetic reprogramming of tumor associated macrophages, which is unique among macrophage targeting strategies.
Login Or Register To Read Full Story